<DOC>
	<DOCNO>NCT01110486</DOCNO>
	<brief_summary>The purpose study determine safety , pharmacokinetics maximum tolerate dose ABT-348 monotherapy give combination carboplatin docetaxel .</brief_summary>
	<brief_title>ABT-348 Monotherapy Combination With Carboplatin Docetaxel Treat Advanced Solid Tumors</brief_title>
	<detailed_description>The primary purpose study determine safety , pharmacokinetics maximum tolerate dose ABT-348 monotherapy give combination carboplatin docetaxel . The secondary purpose study evaluate safety recommend Phase 2 dose evaluate preliminary efficacy data regard objective response rate time progression , duration overall response , ECOG performance status ABT-348 monotherapy give combination carboplatin docetaxel .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histological confirmation locally advance metastatic solid tumor . That either refractory standard care therapy disease standard care therapy reliably effective exists , For carboplatin determine appropriate therapy , per investigator , For docetaxel determine appropriate therapy , per investigator . 2 . Eastern Cooperative Oncology Group Status 02 3 . Serum creatinine value ≤ 1.5 time upper limit normal ( ULN ) either estimate creatinine clearance value determine CockcroftGault formula base 24 hour urine collection creatinine clearance value ≥ 50 mL/min 4 . Adequate liver function demonstrate serum bilirubin &lt; 2 x ULN AST ALT ≤ 2.5 x ULN 5 . Adequate bone marrow demonstrate absolute neutrophil count ( ANC ) ≥ 1,500/mm2 ( 1.5 x 109/L ) ; Platelets ≥ 100,000/mm2 ( 100 x 109/L ) ; Hemoglobin ≥ 9.0 g/dL ( 1.4 mmol/L ) 6 . QTc interval &lt; 500 msec 7 . Left Ventricular Ejection Fraction &gt; 50 % 8 . Women childbearing potential men must agree use adequate contraception ( one follow list ) prior study entry , duration study participation 3 month follow completion therapy . 9 . Capable understand comply parameter outline protocol able sign inform consent , approve Institutional Review Board ( IRB ) prior initiation screen studyspecific procedure . 1 . Subject know active CNS involvement . The subject untreated brain meningeal metastasis . 2 . Subject receive anticancer therapy within period 21 day 5 half life ( whichever short ) prior Study Day 1 3 . Subject unresolved toxicity prior anticancer therapy , grade 2 high clinically significant toxicity ( exclude alopecia ) 4 . Subject major surgery within 28 day prior Study Day 1 5 . Subject currently exhibit symptomatic persistent , uncontrolled hypertension define diastolic blood pressure &gt; 90 mmHg systolic blood pressure &gt; 140 mmHg 6 . Subject proteinuria grade &gt; 1 7 . Subject receive therapeutic anticoagulation therapy . Low dose anti coagulation ( e.g. , low dose heparin warfarin ) catheter prophylaxis permit . 8 . Clinically significant uncontrolled condition ( ) 9.Psychiatric illness/social situation would limit compliance study requirement 10 . Subject know infection HIV , Hepatitis B Hepatitis C 11 . Subject poorly control diabetes mellitus 12 . Subject enrol Arm A , B , C D unable swallow absorb oral tablet normally 13 . Any medical condition opinion study investigator place subject unacceptably high risk toxicity 14 . Female subject lactate pregnant 15 . Subject enrol Arm E hypersensitivity drug formulate polyethoxylated castor oli ( Cremophor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>